Publications
5546 Results
- Journal / Conference
- ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), oral
- Year
- 2024
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1605
Urinary comprehensive genomic profile correlates with risk of recurrence of BCG-unresponsive non-muscle invasive bladder cancer treated with atezolizumab in SWOG S1605
- Journal / Conference
- JNCI-Journal of the National Cancer Institute May 8;116(5):673-680
- Year
- 2024
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID38243705
- PMC
- PMC11077308
- Study Number(s)
- S1609
Correlation Between Tumor Size Change and Outcome in a Rare Cancer Immunotherapy Basket Trial
- Journal / Conference
- Cancer May 15;130(10):1784-1796
- Year
- 2024
- Research Committee(s)
- Melanoma
- PMID
- PMID38261444
- Study Number(s)
- S1221
A phase 1 study of triple targeted therapy with BRAF, MEK and AKT inhibitors for patients with BRAF mutated cancers
- Journal / Conference
- Clinical Cancer Research Apr 15;30(8):1655-1668
- Year
- 2024
- Research Committee(s)
- Lung
- PMID
- PMID38277235
- PMC
- PMC11016892
- Study Number(s)
- S1400I
Multi-omics profiling reveals molecular and immune features associated with benefit from immunotherapy for advanced squamous cell lung cancer patients from the phase III SWOG Lung-MAP S1400I trial
- Journal / Conference
- Leukemia Feb;38(2):389-392
- Year
- 2024
- Research Committee(s)
- Leukemia
- PMID
- PMID38263433
Clinical Evaluation of Complete Remission (CR) with Partial Hematologic Recovery (CRh) in Acute Myeloid Leukemia: A Report of 7,235 Patients from Seven Cohorts Running head: Survival following CRh in AML
- Journal / Conference
- Cancer Research Communications Mar 7;4(3):682-690
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID38363156
- PMC
- PMC10919207
- Study Number(s)
- CTSU/C80802
CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C infection in Patients with advanced hepatocellular carcinoma
- Journal / Conference
- JAMA Network Open Jan 2;7(1):e2351062
- Year
- 2024
- Research Committee(s)
- Lymphoma
- PMID
- PMID38241048
- PMC
- PMC10799264
- Study Number(s)
- S1826
Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children
- Journal / Conference
- European Journal of Cancer Apr:201:113914
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID: 38359495
- Study Number(s)
- CTSU/C80405
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer
- Journal / Conference
- Blood Jan 12:blood.2023021959. doi: 10.1182/blood.2023021959. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Leukemia
- PMID
- PMID38215395
- PMC
- PMC1110309
- Study Number(s)
- CTSU/A041202
Long Term Follow-up from A041202, A Phase 3 Study of Bendamustine/Rituximab vs Ibrutinib or Ibrutinib/Rituximab Shows Continued Efficacy and Safety of Ibrutinib in Older Adults with CLL
- Journal / Conference
- Cancer Sep 1;130(17):2918-2927
- Year
- 2024
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- PMID
- PMID38358334
- PMC
- PMC11309904
- Study Number(s)
- S1609